Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001520138-24-000207
Filing Date
2024-05-15
Accepted
2024-05-14 19:36:43
Documents
74
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q esgh-20240331_10q.htm   iXBRL 10-Q 534341
2 EX-31 esgh-20240331_ex31z1.htm EX-31 12497
3 EX-32 esgh-20240331_ex32z1.htm EX-32 4646
9 GRAPHIC image_01.jpg GRAPHIC 63122
  Complete submission text file 0001520138-24-000207.txt   3963912

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE esgh-20240331.xsd EX-101.SCH 38391
5 XBRL CALCULATION FILE esgh-20240331_cal.xml EX-101.CAL 56779
6 XBRL DEFINITION FILE esgh-20240331_def.xml EX-101.DEF 99282
7 XBRL LABEL FILE esgh-20240331_lab.xml EX-101.LAB 250649
8 XBRL PRESENTATION FILE esgh-20240331_pre.xml EX-101.PRE 208145
77 EXTRACTED XBRL INSTANCE DOCUMENT esgh-20240331_10q_htm.xml XML 470828
Mailing Address 523 SCHOOL HOUSE RD KENNETT SQUARE PA 19348
Business Address 523 SCHOOL HOUSE RD KENNETT SQUARE PA 19348 267-467-5871
ESG Inc. (Filer) CIK: 0001883835 (see all company filings)

EIN.: 871918342 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 000-56532 | Film No.: 24946548
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)